Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03055832 · ClinicalTrials.gov registry record · NA
Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction
A NA study of Meibomian Gland Dysfunction, sponsored by Tear Film Innovations.
- Completed
- Registry status
- NA
- Development phase
- 142
- Enrollment target
- 7
- Study locations
NCT03055832: Completed NA study of Meibomian Gland Dysfunction, sponsored by Tear Film Innovations.
NCT03055832 is a NA study of Meibomian Gland Dysfunction that has completed, run by Tear Film Innovations. The registered enrollment target is 142 participants, above the 85-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (67% higher). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03055832, a NA study of Meibomian Gland Dysfunction, has completed, sponsored by Tear Film Innovations.
- COMPLETED
- Registry status
- NA
- Development phase
- 142 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study was to compare changes in meibomian gland dysfunction (MGD), tear break-up time (TBT) and evaporative dry eye (EDE) symptoms after treatment with either the iLux® 2020 System or the LipiFlow® Thermal Pulsation System.
Primary Outcome
Meibomian glands on the lower eyelid were assessed by the examiner using a Meibomian Gland Evaluator while viewing the eyelid margin using a slit lamp microscope. 5 glands in 3 zones (nasal, medial, temporal) were evaluated. Each gland was scored from 0-3 for a maximum MGS of 45 in each eye. MGS scoring was as follows: 0 = no secretion (worst), 1 = inspissated, 2 = cloudy, 3 = clear liquid (best). A positive change value indicates an improvement.
Conditions Studied
Interventions
- DEVICE iLux 2020 System
- DEVICE LipiFlow Pulsation System
Study Locations (7)
Arizona
- TearFilm Investigative Site - Phoenix
- TearFilm Investigative Site - Scottsdale
Colorado
- TearFilm Investigative Site - Centennial
- TearFilm Investigative Site - Greenwood Village
Missouri
- TearFilm Investigative Site - Chesterfield
- TearFilm Investigative Site - Kansas City
California
- TearFilm Investigative Site - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2017-02-09 |
| Est. Completion | 2017-07-20 |
| Phase | NA |
What the finished NCT03055832 record still lists
NCT03055832 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, above the 85-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (67% higher).
The record links to 1 condition, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which iLux 2020 System is the first listed.
NCT03055832 lists 7 locations in 4 states (Arizona, Colorado, Missouri).
Frequently Asked Questions
What is clinical trial NCT03055832 about?
NCT03055832 is a clinical study titled "Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction". The purpose of this study was to compare changes in meibomian gland dysfunction (MGD), tear break-up time (TBT) and evaporative dry eye (EDE) symptoms after treatment with either the iLux® 2020 System or the LipiFlow® Thermal Pulsation System.
What is the current status of trial NCT03055832?
This trial is currently completed. It is a NA study. The enrollment target is 142 participants. The study started on 2017-02-09. Estimated completion is 2017-07-20.
What conditions does trial NCT03055832 study?
This clinical trial studies the following conditions: Meibomian Gland Dysfunction.
What interventions are being tested in trial NCT03055832?
The interventions under investigation include: iLux 2020 System (DEVICE), LipiFlow Pulsation System (DEVICE).
Who is sponsoring clinical trial NCT03055832?
This trial is sponsored by Tear Film Innovations, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03055832 being conducted?
This trial has 7 study locations across Arizona, California, Colorado, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meibomian Gland Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03055832's enrollment target sits among peer trials
142 2nd of 8 the highest of 8 other Meibomian Gland Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Meibomian Gland Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Meibomian Gland Dysfunction Management
ACTIVE NOT RECRUITING · NA
-
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
ACTIVE NOT RECRUITING · NA
-
The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
COMPLETED · NA
-
Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study
COMPLETED · NA
-
Clinical Study Using Eye Lipid Mobilizer (ELM) With Heat and Vibration To Treat Evaporative Dry Eye Disease
COMPLETED · NA
-
Tear Film Innovations iLux Safety Study
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI